Roivant Sciences Ltd. — Form 8-K
Filed September 8, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Roivant announced positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD). The drug achieved a 56.3% placebo-adjusted reduction in pulmonary vascular resistance (primary endpoint, p<0.0001), a 35.2-meter improvement in six-minute walk distance (p=0.0027), and a 53.2% reduction in NT-proBNP (p=0.0002), with favorable safety. Phase 3 PHrontier trial (375 patients planned) has been initiated and is enrolling.
Why this rating
Strong Phase 2 data in large unmet-need market (200k patients) for first-in-class candidate materially de-risks pipeline asset; Phase 3 initiation accelerates value realization. Meaningful relative to $9.8B market cap and biotech development stage.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $41.33 ▲ 18.33% | at our read · unknown $34.93 | +10 min · unknown $34.93 ▲ 0.00% | +30 min · unknown $41.08 ▲ 17.61% | +1 hr · unknown $40.42 ▲ 15.72% | +4 hrs pending |
The stock had already moved -15.49% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.